Intermediate Dose-Volume Parameters, Not Low-Dose Bath, Is Superior to Predict Radiation Pneumonitis for Lung Cancer Treated With Intensity-Modulated Radiotherapy.

Purpose: Although intensity-modulated radiotherapy (IMRT) is now a preferred option for conventionally fractionated RT in lung cancer, the commonly used cutoff values of the dosimetric constraints are still mainly derived from the data using three-dimensional conformal radiotherapy (3D-CRT). We aimed to compare the prediction performance among different dosimetric parameters for acute radiation pneumonitis (RP) in patients with lung cancer received IMRT.

Methods: A total of 236 patients treated with IMRT were retrospectively reviewed in two independent groups of lung cancer from January 2014 to August 2018. The primary endpoint was grade 2 or higher acute RP (RP2). Dose metrics were generated from the bilateral lung volume outside GTV (Vdose) and PTV (Vdose). The associations of RP2 with clinical variables, dose-volume parameters and mean lung dose (MLD) were analyzed by univariate and multivariate logistic regression. The power of discrimination among each predictor was assessed by employing the bootstrapped area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), and the integrated discrimination improvement (IDI).

Results: Thirty-four (14.4%) out of 236 patients developed acute RP2 after the end of IMRT. The clinical parameters were identified as less important predictors for RP2 based on univariate and multivariate analysis. In both studied groups, the significance of association was more convincing in V20, V30, and MLD (smaller Ps) than V5 and V5. The largest bootstrapped AUC was identified for the V30. We found a trend of better discriminating performance for the V20 and V30, and MLD than the V5 and V5 according to the higher values in AUC, IDI, and NRI analysis. To limit RP2 incidence less than 20%, the V30 cutoff was 14.5%.

Conclusions: This study identified the intermediate dose-volume parameters V20 and V30 with better prediction performance for acute RP2 than low-dose metrics V5 and V5. Among all studied predictors, the V30 had the best discriminating power, and should be considered as a supplement to the traditional dose constraints in lung cancer treated with IMRT.